Abstract This study analysed the effect of selective b 1 -blockade on neuromuscular recruitment characteristics during progressive endurance exercise. Ten healthy subjects ingested a selective b 1 -blocker, acebutolol (200 mg b.d.), for 7 days (for one of two cycling trials), with a 10-day wash-out period between trials. On the last day of acebutolol ingestion subjects performed three successive 15-min rides at 30%, 50% and 70% of their peak power output and then cycled at increasing (15 W min -1 ) work rates to exhaustion. Force output, heart rate, submaximal _ V V O 2 , rate of perceived exertion (RPE), electromyographic (EMG) data and blood lactate were captured during the cycling activity. .05] were significantly lower for the group who ingested b 1 -blockade (BETA) compared to the control group (CON). Although not significant, submaximal _ V V O 2 was reduced in BETA during the ride, while RPE was significantly higher during the ride for BETA (P <0.01). Mean integrated electromyography was higher in the BETA group although these differences were not significant. Mean power frequency values of the BETA group showed a significant (P <0.05) shift to the upper end of the spectrum in comparison to the control group. Lactate values [11.7 (3.5) mmol.l -1 vs 7.1 (4.1) mmol.l -1 CON vs BETA] were significantly lower (P <0.05) at exhaustion in BETA. Significant reductions in cycling performance were found when subjects ingested b 1 -blockers. This study has shown significant shifts to the upper end of the EMG frequency spectrum after b 1 -blocker ingestion, which could be caused by a change in neuromuscular recruitment strategy to compensate for the impaired submaximal exercise performance.
Introduction
Individuals receiving b-adrenergic receptor blocking drugs often complain of muscle fatigue. Both non-selective b 1 -+ b 2 -blockers and selective b 1 -blockers reduce most individuals' capacity to exercise (Hughson 1989; Verstappen and van Baak 1987) . b-Blockade either increases (Broberg et al. 1988; Macdonald et al. 1984) or has no effect on plasma lactate accumulation during exercise (Hughson 1989; Lundborg et al. 1981; . and it does not increase muscle glycogenolysis (Cleroux et al. 1989; Kaiser et al. 1986) . Plasma glucose concentration during exercise is either decreased (Lundborg et al. 1981; Macdonald et al. 1984; van Baak and Mooij 1994; Verstappen and van Baak 1987) or unaffected by bblockade (Gullestad et al. 1989; Laustiola et al. 1983) . Only the mobilisation of non-esterified fatty acids (NEFA) is consistently decreased by b-blockade (Laustiola et al. 1983; Lundborg et al. 1981; Uusitupa et al. 1982; van Baak et al. , 1993 . However, whether lower plasma glucose or NEFA concentration is involved in the reduced exercise endurance capacity during b-blockade is open to question. Intravenous infusion studies have shown that reversal of the decreases in circulating glucose and NEFA concentrations with bblockade do not improve exercise capacity (van Baak Since changes in metabolism do not readily explain the impaired sub-maximal exercise capacity during bblockade, other potential causes of early fatigue have to be considered. One possibility is that b-blockade may affect muscle recruitment activity from the central pathways of control. In cycle exercise the integrated electromyographic (IEMG) activity is known to increase with increased exercise intensity (Bigland-Ritchie and Woods 1974) . During continual heavy work at a constant load, an increase in IEMG is observed and interpreted as a sign of muscle contraction failure (Lippold et al. 1960) . More information detailing the motor unit action potentials can be gained by studying the mean power frequency spectrum (MPFS).
To the authors' knowledge, the only experiment that has been conducted to study the influence of b-blockers on the EMG pattern under exercise conditions was by Tesch et al. (1984) , who discovered no differences in IEMG or MPFS during cycling, but did find a decrease in MPFS during b-blockade in comparison to the control group. This could be indicative of muscle fatigue or decreased muscle fibre conduction velocity (v MFC ) (Merletti and Roy 1996; Mortimer et al. 1970) . MPFS was calculated by describing data captured at 90 W initial work rate, and all subsequent data was normalised against it. However, this normalisation technique can be questioned as Ebenbichler et al. (1998) concluded that maximal voluntary contraction (MVC) is the most reliable form of reference when conducting MPFS analyses. This has to be considered throughout investigation of biological signals in which the electrical and mechanical activities of the recruited motor units are summated (Esposito et al. 1998) . Derman (1993) examined IEMG patterns of exercising subjects ingesting b-blockade and found no difference in MVC but significantly higher IEMG activity.He concluded that the higher IEMG was due to additional recruitment of nonfatigued skeletal muscle fibres to maintain the same work rate. However, in this study MPFS was not determined. Therefore, the hypothesis for this study is that during submaximal exercise to exhaustion, b 1 -blocker ingestion will result in an altered neuromuscular recruitment pattern, shown by both the IEMG and MPFS signal. Accordingly, we examined the effects of acebutolol, a selective b 1 -blocker with intrinsic sympathetic activity on IEMG and MPFS during successive cycle rides at 30%, 50% and 70% of peak work rate and at fatigue.
Methods

Subjects
Ten healthy males who were physically active on a regular basis volunteered for the study. Three subjects were unable to complete due to adverse effects such as headaches, dizziness and nausea whilst ingesting beta blockade. The mean age (SD) of the remaining subjects was 26.1 (2.1) years (range 23-30 years), height 181 (9) cm (range 169-194 cm), mass 78.6 (9.7) kg (range 62-94 kg) and percent body fat 14.8 (2.7)% (range 10.6-17.7%). The mean lean thigh volume (V LT ) was 6,492 (928) cc (range 4,629-7,381 cc). All subjects were well-informed about possible risks associated with the experiment and gave their informed consent before participation.
Preliminary testing
To determine peak power output ( _ W W peak ), a modified protocol as described by Hawley and Noakes (1992) was used. Subjects performed a 10-min warm-up on an electrically braked cycle ergometer (Lode, Groningen, Netherlands). The starting power output was determined by multiplying the subject's body mass by 2.5 W. The load was subsequently increased every 150 s by, first, 50 W and then by 25 W until the subjects were unable to maintain force output, or pedalling frequency dropped from 90 to <50 rev min -1 . _ W W peak was defined as the last completed work rate in watts plus the fraction of time spent in the final non-completed work rate, multiplied by 25 W.
Tablet ingestion
Following the progressive exercise tests, the subjects ingested acebutolol for one of the two phases of the trial in a random order. The trials took place over 1-week periods with a 10-day wash out in between trials. Subjects were instructed to consume two 200 mg capsules between 0700 and 0900 hours before breakfast for a period of 7 days.
Blood sampling
On the last day of each phase the subjects were instructed to report to the laboratory. An 18-guage Teflon cannula (Jelco, Johnson and Johnson, Halfway house, South Africa) was positioned in an antecubital vein and connected to a three-way stop cock (Uniflex, Mallinckrodt, Hennef-Seig, Germany). This cannula was flushed periodically with 2-3 ml of sterile saline containing heparin (5 IU ml -1 ) and was used for the collection of venous blood samples (10 ml) at rest and during exercise. Venous blood samples (10 ml) were drawn at rest, at the end of each 15 min work rate and at exhaustion. The samples were then divided into aliquots, which were put into an ice-cold tube containing potassium oxalate and sodium fluoride for later determinations of lactate concentrations. The tubes were centrifuged at 3,000 g for 10 min at 4°C immediately after the completion of the trial and the supernatants were stored at -20°C for later analyses of plasma lactate. Plasma lactate concentrations was measured with spectrophotomeric (Beckman model 35; Beckman Instruments, Fullerton, Calif, USA) enzymatic assays (Lactate PAP, BioM rieux, Lyon, France; NEFA half-micro test; Boehringer Manheim, Germany).
Maximal isometric voluntary contraction
To normalise EMG recordings during cycling it was first necessary to perform maximal isometric force output testing (Hunter et al. 2002) , which is not affected by b-blocker ingestion (Derman et al. 1993) . The strength of the subjects' right knee extensors was measured on an isokinetic dynamometer (Kin-Com Chattanooga Group Inc., USA). Subjects sat on the dynamometer and their hips, thighs and upper bodies were firmly strapped to the seat. In this position their hip was at 100°angle of flexion. The right lower leg was then attached to the arm of the dynamometer at a level slightly above the lateral malleolus of the ankle joint and the axis of rotation of the dynamometer arm was aligned with the lateral femoral condyle. The dynamometer arm was then set so that the knee was at a 60°angle from full leg extension. Each subject performed four sub-maximal familiarisation contractions prior to performing two maximal MVCs, the latter of which was used for subsequent analyses. All subjects were encouraged verbally to exert maximal effort during both MVCs.
Progressive submaximal exercise
As with the preliminary _ W W peak testing, Lode cycle ergometers were used. After taking a venous blood sample and measures of heart rate at rest, the subjects performed three successive 15-min rides at 30, 50 and 70% of their _ W W peak and subsequently cycled at increasing 15 W min -1 until they could not maintain force (Fig. 1) . The same ride was performed for both the controls (CON) and the group ingesting b-blocker (BETA).
Recordings of heart rate and perceived exertion Heart rate was recorded at rest and then recorded along with rate of perceived exertion (RPE) (Borg 1973) at 10, 25, 40 min and at exhaustion (Fig. 1) .
During the final 5 min of each 15-min work rate and at exhaustion, subjects wore and breathed through a mask connected to an Oxycon Alpha automated gas analyser (Mijnhardt, The Netherlands). Before each test, the analyser was calibrated with a Hans Rudolph 5530, 3L syringe (Vacuumed, Ventra, USA), room air and a 5% CO 2 : 95% N 2 gas mixture. Analyser outputs were processed by a computer, which calculated 1 min ventilation, oxygen consumption and carbon dioxide production values for each breath.
Oxygen consumption values were the average of the highest values measured over 60 s in the final work rate. _ V V O 2 was then determined by dividing the oxygen consumption value by the body mass of the subject (ml kg -1 min -1 ).
EMG testing
Prior to maximal isometric strength testing on the Kin-Com isokinetic dynamometer, EMG electrodes were attached to the subject's lower limb midway between the superior surface of the patella and the anterior superior iliac crest of the ''belly'' of the rectus femoris. The overlying skin on the muscles was carefully prepared: hair was shaved off, the outer layer of epidermal cells abraded, and oil and dirt were removed from the skin with an alcohol pad. Triode electrodes (Thought Technology, USA) were placed on the muscle sites, as described above, and linked via a fibre-optic cable to the Flexcomp/DSP EMG apparatus (Thought Technology) and host computer. The electrodes were heavily taped down with cotton swabs to minimise sweat-induced interference. The EMG data were filtered with a 50 Hz line filter to prevent interference from electrical sources and automatically anti-aliased by the hardware (Thought Technology). Each activity was sampled at a 1,984 Hz capture rate for 5-s bouts. Recordings were taken on the second maximal isometric trial and during the cycling trial at 10, 25, 40 min and exhaustion, thus yielding a raw signal. MVC EMG data were recorded before both cycle rides to ensure similar normalisation of EMG in both trials. The raw data were divided into five 5-s epochs. The first epoch included all data collected during the second MVC trial, and the remaining four epochs included data collected on the ride at 10, 25, 40 min and at exhaustion. The EMG signals were full-wave rectified, movement-artefact removed using a high-pass second-order Butterworth filter with a cut-off frequency of 15 Hz, then smoothed with a low-pass secondorder filter with a cut-off frequency of 5 Hz. This was performed using MATLAB gait analyses software. The integrated data (IEMG) were used for subsequent analyses.
The spectrum of the frequency for each epoch of data collected during the cycle ride was assessed using the raw EMG data by using a fast Fourier transformation algorithm. The analyses for frequency spectrum were restricted to frequencies in the 5-500 Hz range, because the EMG signal content consists mostly of noise outside this bandwidth. The frequency spectrum from each epoch of data was compared with that derived from the MVC, and the amount of spectral compression was estimated. This technique was performed as described by Lowery et al. (1998) , which is a modification of the work of Lo Conte and and Merletti and Lo Conte (1995) . The spectrum of the raw signal of each epoch was obtained and the normalised cumulative power at each frequency was calculated for each epoch. The shift in percentile frequency was examined (e.g. at 0%...50%...100% of the total cumulative) and the percentile shift was then estimated by calculating the mean shift in all percentile frequencies throughout the mid-frequency range (i.e. 5-500 Hz). This method has been suggested as a more accurate estimate of spectral compression than median frequency analysis, which uses a single value of (50th) percentile frequency (Lowery et al. 1998 ). This change in MPFS data was used for subsequent analyses.
Statistical analyses
A two-way ANOVA for repeated measures was used to evaluate statistical significance of differences between groups, changes over time and the interaction of these variables. Post hoc analyses of the main effects over time were done using a Scheffe´'s test. Single comparisons between treatments were analysed with a paired Student's t-test using two-tailed values of P. Significance was accepted at P £ 0.05. All data are expressed as means (SD).
Results
Significantly lower values (P <0.05) during the cycle ride were found in BETA compared to CON for _ W W peak (P <0.01) and time to exhaustion (TIME) in BETA (Table 1) .
Heart rate increased significantly less (P <0.05) (Fig.2) for BETA in comparison to CON and both groups responded similarly over time. Mean heart rate for the total ride was 111.5 (30.0) beats min -1 for BETA and 135.5 (38.3) beats min -1 for CON. In BETA the reduced heart rate was accompanied by a trend for lower submaximal _ V V O 2 values with both groups increasing Fig. 1 Progressive cycle exercise test protocol. Rate of perceived exertion (RPE), electromyography (EMG), heart rate (HR) and _ V V O 2 were all recorded at 10, 25, 40 min and exhaustion during the ride significantly over time (P <0.05) (Fig. 3) . Mean submaximal _ V V O 2 values for the duration for the ride were 32.0 (8.3) ml kg -1 min -1 for BETA and 38.1 (9.6) ml kg -1 min -1 for CON. RPE was significantly greater for BETA than CON (P <0.01) (Fig. 4) and mean RPE values for the total ride were 6.1 (3.6) for BETA and 4.7 (3.6) CON.
IEMG values showed a trend to increase by 34.7, 30.2, 44.1 and 64.4% at 10, 25, 40 min and exhaustion, respectively, for BETA in comparison to CON. The BETA group also showed a large standard deviation for IEMG data at exhaustion (Fig. 5) . The mean IEMG for the total ride was 56.9 (25.4)% for BETA and 29.4 (4.0)% for CON. There was a significant (P <0.05) shift to the upper portion of MPFS in BETA with a mean of 1.15 (0.03) in comparison to a shift to the lower portion of MPFS in CON, which showed an average of 0.78 (0.07) for the total ride (Fig. 6) .
Lactate concentrations were significantly less for BETA in comparison to CON [7.1 (4.1) mmol l -1 BETA; 11.7 (3.5) mmol l -1 CON] at exhaustion (Fig. 7 ) (P <0.01).
Discussion
The results of this study indicate that b-blockade significantly affects neuromuscular recruitment activity during submaximal exercise. Maximal exercise capacity was reduced by ingestion of selective b 1 -blockade, as reported by most investigators (Gullestad et al.1989 ; Table 1 Peak power output ( _ W W peak ) reached at the point of cycling exhaustion and time (min) taken to reach exhaustion (TIME) for both control (CON) and subjects who have ingested b-blockers (BETA **P <0.01 _ W W peak CON vs BETA *P <0.05 TIME CON vs BETA Fig. 2 Heart rate values captured at rest, 10, 25, 40 min and exhaustion during the cycle ride for the b-blocker group (BETA) and the control group (CON) (*P <0.05 between groups and increase over time without interaction) Kullmer et al. 1987) . The impaired maximal exercise capacity may reduce heart rate and _ V V O 2 as is shown in this study. It is also well documented that an increased perception of effort will reduce exercise performance in healthy individuals who have ingested b-blocker (Joyner et al. 1986; Wilmore et al. 1985) , which is shown in this study by an increase in RPE for BETA. It is has been proposed that this increase in perception of effort results from an inability of healthy individuals to compensate for the decrease in heart rate by increasing stroke volume as it is has been maximised as an adaptation effect of exercise training (Head 1999) . These changes in RPE may also be related to neuromuscular recruitment differences as shown in this study.
The tendency for IEMG to increase in the BETA group may be a result of a significant reduction in exercise tolerance. Similar results were obtained by Derman (1993) , who suggested that this IEMG increase could be due to a central mechanism projecting increased neural output owing to the reduced maximal exercise capacity. Also, Moritani and Yoshitake (1998) showed a linear increase for IEMG/ _ V V O 2 in normal subjects. However the BETA group had a significantly lower _ V V O 2 , yet IEMG was higher. This would indicate that there is a higher neural input to compensate for the reduced _ V V O 2. Another possibility is that there was a higher recruitment of non-fatigued muscle fibres (Derman 1993) when subjects were on b-blockers.
The large standard deviations for final force output and IEMG activity in the BETA group show that certain subjects are more vulnerable to reduced exercise tolerance when ingesting b-blockers. This finding is supported by Derman (1993) who showed that not all the subjects' performance capacities were equally affected following the ingestion of b-blockers.
There was a significant shift to the upper portion of MPFS in BETA, which indicates an increase in firing rate to recruit more motor units (Bernardi et al. 1997) in response to the reduced exercise capacity (Hagberg 1981; Komi and Tesch 1979; Mortimer et al. 1970; Petrofsky and Lind 1980) . This shift towards the upper portion of MPFS could have been caused by an increase in v MFC (Bigland-Ritchie et al. 1981 ) from an up-regulation in central command (Lago and Jones 1977; Zwarts et al. 1987 ). This change in central command may be an attempt to recruit more type II muscle fibres as b-blockade will cause the impairment of type I fibres during cycling (Kaiser et al. 1981) , resulting in a greater use of type II fibres, which have a lower fatigue threshold. Furthermore, this finding is supported by Kupa et al. (1995) , who showed that the greater proportion of type II muscle fibres would result in a shift to the upper end of the spectrum. This is due to type II fibres having a greater maximum rate of repolarisation and depolarisation compared to type I fibres and producing an action potential that has a lesser duration (Kupa et al. 1995) . Action potentials of shorter duration contribute high-frequency components to the EMG spectrum and produce a greater value of MPFS (Kupa et al. 1995) . This increased use of type II fibres, which have a lower fatigue threshold, may have also been a factor in the early termination of exercise in BETA. However, it is also possible that the difference in MPFS could be from muscle changes. First, it has been suggested that the decline in MPFS is a result of increased lactate concentrations causing a lowering of pH (Juel 1988 ) and a consequent reduction in v MFC (Broman et al. 1985; De Luca 1984; Merletti et al. 1984; Mortimer et al. 1970) . In this study, lactate concentrations were significantly less for BETA, which does suggest a possible cause for the difference in MPFS. Conversely, it has also been shown in McArdle disease patients that MPFS declined during MVC, in the absence of any lactate and v MFC changes, therefore suggesting that factors other than increasing lactate would influence v MFC (Linssen et al. 1990 ). The change in MPFS could also be from an increase in muscle temperature in BETA as the reduced cardiovascular capacity will be requiring a higher amount of effort to sustain the same given workload as CON. BiglandRitchie (1981) showed that by heating a muscle it would increase conduction velocity and therefore produce a shift to the upper portion of MPFS. Fig. 7 Lactate samples taken at rest, at 15 min during the ride and at exhaustion in both CON and BETA groups (**P <0.01 main effect between groups and over time)
Blood lactate concentrations were lower in the BETA group at fatigue, which is supported by some investigators (Astrom 1968; Juhlin-Dannfelt and Astrom 1979) . However, other studies show conflicting results (Head 1999) . In our study, BETA subjects fatigued at lower power outputs, which will inevitably cause a decrease in absolute lactate values. Therefore, reduced lactate may be caused simply by reduced cycling intensity at fatigue. However, if as previously mentioned, type II fibres are preferentially recruited in the BETA group, higher lactate values would be expected in the BETA group.
In conclusion, this study supports earlier studies that selective b 1 -blockade will limit prolonged exercise endurance. Furthermore, this study has shown that subjects who have ingested b-blockers have an altered EMG frequency spectrum, which could result from a change in the neuromuscular recruitment strategy to maintain submaximal power in compensation for the impaired exercise performance.
